By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ALK-Abello A/S 

Bøge Allé 6-8

Hørsholm    DK-2970  Denmark
Phone: 45-45-74-74-45 Fax: 45-45-74-89-90



Company News
ALK-Abello A/S Release: Three-Month Interim Report (Q1) 2017 5/9/2017 10:15:47 AM
ALK-Abello A/S Release: Release Date Of Three-Month Interim Report (Q1) 2017 And Audio Cast 5/3/2017 10:50:08 AM
ALK-Abello A/S Release: ACARIZAX Approved In Europe For Use In Adolescent Patients With House Dust Mite-Induced Allergic Rhinitis 4/17/2017 8:25:58 AM
ALK-Abello A/S's ACARIZAX Data Results In Significant Change To The GINA Asthma Management Strategy: Sublingual Allergy Immunotherapy (SLIT) Recommended As A Treatment Option In Patients With House Dust Mite Allergic Asthma 2/27/2017 8:49:56 AM
Merck & Co. (MRK) to Terminate Allergy Agreement With ALK-Abello A/S 7/27/2016 8:27:26 AM
JAMA Publishes Phase III Data From Allergic Asthma Trial With ALK-Abello A/S's House Dust Mite SLIT-Tablet, ACARIZAX 4/26/2016 9:58:04 AM
ALK-Abello A/S And Abbott (ABT) Expand Partnership Into South-East Asian Growth Markets 1/28/2016 7:38:11 AM
ALK-Abello A/S Release: New Product Product (ACARIZAX) For For Treatment Of House Dust Mite Allergic Rhinitis And Asthma Obtains Reimbursement In Denmark 12/9/2015 7:24:43 AM
ALK-Abello A/S To Participate At The Goldman, Sachs & Co. Biotech And Emerging Pharma Symposium In London 8/20/2015 8:12:27 AM
ALK-Abello A/S To Present At The Morgan Stanley Global Healthcare Conference In New York 8/19/2015 7:52:15 AM